Amgen Stops Rilotumumab Clinical Trials

November 25, 2014 11:51 AM

3 0

Amgen Stops Rilotumumab Clinical Trials

Amgen Inc on Monday announced that it has stopped its two clinical trials on an experimental cancer drug called rilotumumab due to a sudden increase in deaths among the study patients. Rilotumumab is a novel drug that has been developed in-house to treat stomach cancer.

The California-based biopharmaceutical company in a statement said that an independent safety panel noted that patients who were given a combination of experimental drug and chemotherapy were dying after receiving it, as compared to those who were given only chemotherapy.

Also read: Deutsche Bank Gets a Much-Needed Boost Working for Big Tobacco

Read more

To category page